DE602004023324D1 - Pyrrolotriazinverbindungen als kinaseinhibitoren - Google Patents

Pyrrolotriazinverbindungen als kinaseinhibitoren

Info

Publication number
DE602004023324D1
DE602004023324D1 DE602004023324T DE602004023324T DE602004023324D1 DE 602004023324 D1 DE602004023324 D1 DE 602004023324D1 DE 602004023324 T DE602004023324 T DE 602004023324T DE 602004023324 T DE602004023324 T DE 602004023324T DE 602004023324 D1 DE602004023324 D1 DE 602004023324D1
Authority
DE
Germany
Prior art keywords
kinase inhibitors
pyrrolotriazine compounds
pyrrolotriazine
compounds
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004023324T
Other languages
English (en)
Inventor
Brian E Fink
Ashvinikumar V Gavai
Gregory D Vite
Ping Chen
Harold Mastalerz
Derek J Norris
John S Tokarski
Yufen Zhao
Wen-Ching Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE602004023324D1 publication Critical patent/DE602004023324D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004023324T 2003-12-29 2004-12-23 Pyrrolotriazinverbindungen als kinaseinhibitoren Active DE602004023324D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53333503P 2003-12-29 2003-12-29
PCT/US2004/043169 WO2005066176A1 (en) 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602004023324D1 true DE602004023324D1 (de) 2009-11-05

Family

ID=34748887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023324T Active DE602004023324D1 (de) 2003-12-29 2004-12-23 Pyrrolotriazinverbindungen als kinaseinhibitoren

Country Status (32)

Country Link
US (4) US7141571B2 (de)
EP (2) EP2058314A1 (de)
JP (1) JP4740878B2 (de)
KR (1) KR100839716B1 (de)
CN (1) CN1922182B (de)
AR (1) AR047076A1 (de)
AT (1) ATE443706T1 (de)
AU (1) AU2004312413C1 (de)
BR (1) BRPI0418231A (de)
CA (1) CA2552107C (de)
CL (1) CL2009001492A1 (de)
CY (1) CY1109662T1 (de)
DE (1) DE602004023324D1 (de)
DK (1) DK1699797T3 (de)
ES (1) ES2331842T3 (de)
GE (1) GEP20105081B (de)
HK (1) HK1088332A1 (de)
HR (1) HRP20090601T1 (de)
IL (1) IL176450A0 (de)
MX (1) MXPA06007038A (de)
MY (1) MY145634A (de)
NO (1) NO20062763L (de)
NZ (2) NZ573544A (de)
PE (1) PE20050679A1 (de)
PL (1) PL1699797T3 (de)
PT (1) PT1699797E (de)
RU (1) RU2373209C2 (de)
SI (1) SI1699797T1 (de)
TW (1) TWI332840B (de)
UA (1) UA89038C2 (de)
WO (1) WO2005066176A1 (de)
ZA (1) ZA200605160B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
PL219736B1 (pl) * 2002-04-23 2015-07-31 Bristol Myers Squibb Co Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
ATE421510T1 (de) 2005-03-28 2009-02-15 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
ES2432361T3 (es) * 2005-12-02 2013-12-03 Bayer Healthcare, Llc Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
US8063208B2 (en) * 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
WO2008057863A1 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
EP2115130B1 (de) 2007-02-08 2011-08-03 Codexis, Inc. Ketoreduktasen und anwendungen davon
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
KR20100101666A (ko) * 2007-12-19 2010-09-17 제넨테크, 인크. 8-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd 1−置換−トランス−4−(置換アミノ)ピペリジン−3−オールの製造方法
EP2344504B1 (de) * 2008-10-08 2014-06-04 Bristol-Myers Squibb Company Pyrrolotriazin-kinaseinhibitoren
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
JP5662346B2 (ja) 2009-01-21 2015-01-28 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG 新規二環式抗生物質
IN2012DN01251A (de) * 2009-07-28 2015-05-15 Ube Industries
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
EP2589592B1 (de) 2010-06-30 2018-08-22 FUJIFILM Corporation Neue nikotinamid-derivate oder salze davon
CN102153558B (zh) * 2011-02-23 2012-11-21 扬州永济医药新技术有限公司 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
SI3094329T1 (sl) * 2014-01-13 2019-02-28 Aurigene Discovery Technologies Limited Biciklični heterociklilni derivati kot inhibitorji IRAK4
AU2015259294A1 (en) * 2014-05-12 2016-12-01 Quest Diagnostics Investments Llc Quantitation of tamoxifen and metabolites thereof by mass spectrometry
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
US20240132521A1 (en) * 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
JP4623483B2 (ja) 1999-08-23 2011-02-02 塩野義製薬株式会社 sPLA2阻害作用を有するピロロトリアジン誘導体
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
NZ525334A (en) 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
PL219736B1 (pl) 2002-04-23 2015-07-31 Bristol Myers Squibb Co Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
EP1503996B1 (de) * 2002-04-23 2008-12-24 Bristol-Myers Squibb Company Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
US6894066B2 (en) 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
BRPI0418231A (pt) 2007-04-27
CN1922182A (zh) 2007-02-28
RU2006127396A (ru) 2008-02-10
GEP20105081B (en) 2010-09-27
HK1088332A1 (en) 2006-11-03
ZA200605160B (en) 2007-12-27
CN1922182B (zh) 2010-08-18
AU2004312413A1 (en) 2005-07-21
US20090048244A1 (en) 2009-02-19
US20050182058A1 (en) 2005-08-18
US7297695B2 (en) 2007-11-20
TW200526226A (en) 2005-08-16
EP1699797A1 (de) 2006-09-13
US7846931B2 (en) 2010-12-07
US20110039838A1 (en) 2011-02-17
MXPA06007038A (es) 2006-08-31
ES2331842T3 (es) 2010-01-18
US7141571B2 (en) 2006-11-28
AR047076A1 (es) 2006-01-04
PT1699797E (pt) 2009-12-29
EP2058314A1 (de) 2009-05-13
CA2552107C (en) 2011-10-18
RU2373209C2 (ru) 2009-11-20
PE20050679A1 (es) 2005-09-25
DK1699797T3 (da) 2010-01-04
UA89038C2 (en) 2009-12-25
NO20062763L (no) 2006-09-11
US20060264438A1 (en) 2006-11-23
AU2004312413B2 (en) 2010-07-22
TWI332840B (en) 2010-11-11
KR100839716B1 (ko) 2008-06-19
CL2009001492A1 (es) 2010-01-15
EP1699797B1 (de) 2009-09-23
KR20060107828A (ko) 2006-10-16
NZ548070A (en) 2009-02-28
SI1699797T1 (sl) 2010-04-30
PL1699797T3 (pl) 2010-02-26
AU2004312413C1 (en) 2011-01-27
JP2007518721A (ja) 2007-07-12
CA2552107A1 (en) 2005-07-21
ATE443706T1 (de) 2009-10-15
JP4740878B2 (ja) 2011-08-03
CY1109662T1 (el) 2014-08-13
NZ573544A (en) 2010-04-30
WO2005066176A1 (en) 2005-07-21
IL176450A0 (en) 2006-10-05
MY145634A (en) 2012-03-15
HRP20090601T1 (hr) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE418546T1 (de) Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DE602005020465D1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
IS8108A (is) Ný efnasambönd
SE0302305D0 (sv) Novel Compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8228A (is) Ný asetídínefnasambönd
ATE455768T1 (de) Triazolsubstituierte aminobenzophenonverbindungen
IS8089A (is) Efnasambönd
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
IS8292A (is) Ný efnasambönd
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
ATE411027T1 (de) Benzazepin-derivate als mao-b-hemmer
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
NO20031736D0 (no) Forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition